Name: NAMSW Income Statement - Newamsterdam Pharma Co. Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

NAMSW - Newamsterdam Pharma Co. NV

USD | NASDAQ | Healthcare

NAMSW Income Statement - Newamsterdam Pharma Co. Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23
Revenues
Revenues	3.0	0.0	0.3	19.1	3.0	12.8	29.1	2.3	1.4	0.8	2.9	1.7	8.6
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	38.0	38.6	31.0	27.5	44.8	34.9	35.7	38.4	42.4	41.3	43.4	34.3	40.4
Selling General & Administrative
Operating Income
Operating Income	(58.4)	(66.0)	(55.1)	(35.6)	(68.9)	(43.2)	(25.0)	(52.6)	(55.5)	(51.1)	(49.6)	(42.5)	(39.9)
Non-Operating
Interest Income	5.7	6.5	6.7	7.1	7.4	4.5	4.4	4.9	3.1	2.7	3.1	4.6	0.9
Interest Expense	-
Tax & Net
Income Tax Expense	-	-	-	-	-	-	(0.0)	-	-	-	-	-	-
Net Income From Continuing Ops	(48.4)
Per Share
EPS Basic	(0.40)	-	(0.61)	(0.15)	(0.34)	-	(0.18)	(0.41)	(1.06)	-	(0.57)	(0.47)	(0.51)
EPS Diluted	(0.40)
Supplementary Data
EBITDA	(58.4)	(66.0)	(55.0)	(35.5)	(68.9)	(43.3)	(24.9)	(52.5)	(55.5)	-	-	-	(39.8)
EBIT	(58.4)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues
Revenues	22.6	22.5	45.6	14.1	102.7	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses
Research & Development	135.1	141.8	151.4	159.4	86.7	29.0
Selling General & Administrative	102.7	106.4	70.4	37.6	19.5	6.0
Operating Income
Operating Income	(215.2)	(225.7)	(176.3)	(183.0)	(3.6)	(35.0)
Non-Operating
Interest Income	25.9	27.6	16.9	11.3	-	-
Interest Expense	-	-	-	-	0.3	0.4
Income From Equity Investments
Tax & Net
Income Tax Expense	-	-	(0.0)	0.0	-	-
Net Income From Continuing Ops	(212.7)	(203.8)	(241.6)	(176.9)	(22.6)	(41.8)
Net Income From Discontinued Ops
Per Share
EPS Basic	(1.75)	(1.72)	(2.56)	(2.15)	(1.19)	(3.81)
EPS Diluted	(1.75)	(1.72)	(2.56)	(2.15)	(1.19)	(3.81)
Shares Basic
Supplementary Data
EBITDA	(214.9)	(225.5)	(176.2)	(182.9)	(3.5)	(35.0)
EBIT	(215.2)	(225.7)	(176.3)	(183.0)	(3.6)	(35.0)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)